MHLW Revises Imfinzi’s Optimal Use Guidelines for NSCLC, Calling for PD-L1 Expression Test

    November 15, 2018
    The Ministry of Health, Labor and Welfare (MHLW) has updated the optimal use promotion guidelines for AstraZeneca’s anti-PD-L1 antibody Imfinzi (durvalumab) for the treatment of non-small cell lung cancer (NSCLC), recommending the confirmation of PD-L1 expression levels in patients. Based...read more